Compare Johnson Controls International PLC (JCI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs Novo Nordisk A/S — how do they compare? Johnson Controls International PLC trades at $141.07 (market cap $85.03B), while Novo Nordisk A/S trades at $49.4 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 2.6× Johnson Controls International PLC's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| JCI | NVO | |
|---|---|---|
Market Cap | $85.03B | $220.53B |
Sector | Industrials | Health |
52-Week High | $148.21 | $71.70 |
52-Week Low | $103.24 | $35.29 |
Enterprise Value | $93.86B | $239.49B |
Dividend Yield | 1.15% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson Controls (JCI) trades at $139.03, down 1.02% today, with technical indicators showing bearish momentum despite strong analyst support. The company demonstrates solid fundamentals with Q1 2026 EPS beating expectations at $1.19 versus $1.12, maintaining a pattern of earnings outperformance. Recent corporate developments include a $0.40 dividend declaration and board appointments, while cash flow trends show improvement with projected positive net cash flow of $157M for 2026.
JCI presents a compelling investment case with 62% analyst buy ratings and a $158.29 consensus price target offering 14% upside. However, elevated valuation multiples (P/E 42.95, EV/EBITDA 26.89) and bearish technical signals warrant caution. Key risks include competitive pressures in building technologies and sensitivity to commercial construction cycles, balanced by strong profitability margins and institutional confidence.
Novo Nordisk (NVO) trades at $49.68, down 1.27% on the day, amid a bullish technical signal from moving averages. The company demonstrates robust fundamentals with a trailing P/E of 12.08 and a net income margin of 37.2%, supported by three consecutive quarterly earnings beats. Recent positive catalysts include EU and Indian regulatory approvals for its oral Wegovy weight-loss pill, expanding its GLP-1 franchise.
The outlook remains positive given strong analyst consensus (57.9% Buy ratings) and projected earnings growth, though risks include intensifying competition in the weight-loss drug market and potential margin pressure. The stock presents a compelling opportunity for investors seeking exposure to a profitable leader in metabolic diseases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
